Article Information
History
- April 14, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Xiang-Sha Kong1,*,
- Feng Liu1,*,
- Hai-Bo Wang2,
- Rui-Feng Yang1,
- Dong-Bo Chen1,
- Xiao-Xiao Wang1,
- Feng-Min Lu1,3,#,†,
- Hui-Ying Rao1,#,† and
- Hong-Song Chen1,#,†
- 1Peking University People’s Hospital, National Clinical Research Center for Infectious Disease, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing 100044, China
- 2Peking University Clinical Research Institute, Beijing 100191, China
- 3State Key Laboratory of Natural and Biomimetic Drugs, Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China
- ↵†Corresponding author’s E-mail:
chenhongsong{at}bjmu.edu.cn; rao.huiying{at}163.com; lu.fengmin{at}hsc.pku.edu.cn
Authors’ contribution: Study design: Hong-Song Chen, Hui-Ying Rao and Feng-Min Lu
Data collection: Xiang-Sha Kong, Feng Liu, Rui-Feng Yang, Dong-Bo Chen, Xiao-Xiao Wang
Data interpretation: Xiang-Sha Kong and Feng Liu
Statistical analysis: Hai-Bo Wang and Xiang-Sha Kong
Manuscript writing: Xiang-Sha Kong and Feng Liu
Critical revision of the manuscript: Hong-Song Chen, Hui-Ying Rao and Feng-Min Lu
Posted April 14, 2020.
Epidemic prevention and control measures in China significantly curbed the epidemic of COVID-19 and influenza
